

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

204654Orig1s000

MEDICAL REVIEW(S)

CLINICAL REVIEW

Application Type	NDA
Application Number(s)	204654
Priority or Standard	Standard
Submit Date(s)	September 27, 2012
Received Date(s)	September 28, 2012
PDUFA Goal Date	July 28, 2013
Division / Office	DBRUP/ODE III
Reviewer Name(s)	Daniel Davis, MD
Review Completion Date	June 28, 2013
Established Name	norethindrone acetate/ethinyl estradiol (EE) chewable tablets, ethinyl estradiol tablets and ferrous fumarate (FF) tablets
(Proposed) Trade Name	to be determined
Therapeutic Class	Hormonal contraception
Applicant	Warner Chilcott Company, LLC
Formulation(s)	Chewable tablet; tablet
Dosing Regimen	1 active chewable tablet for 24 days; 1 EE tablet for 2 days; 1 iron tablet for 2 days
Indication(s)	Prevention of pregnancy
Intended Population(s)	Women of reproductive age

Table of Contents

1	RECOMMENDATIONS/RISK BENEFIT ASSESSMENT	5
1.1	Recommendation on Regulatory Action	5
1.2	Risk Benefit Assessment.....	5
1.3	Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ...	5
1.4	Recommendations for Postmarket Requirements and Commitments	5
2	INTRODUCTION AND REGULATORY BACKGROUND	6
2.1	Product Information	6
2.2	Tables of Currently Available Treatments for Proposed Indications	6
2.3	Availability of Proposed Active Ingredient in the United States	7
2.4	Important Safety Issues with Consideration to Related Drugs.....	7
2.5	Summary of Presubmission Regulatory Activity Related to Submission	8
2.6	Other Relevant Background Information	8
3	ETHICS AND GOOD CLINICAL PRACTICES.....	8
3.1	Submission Quality and Integrity	8
3.2	Compliance with Good Clinical Practices	9
3.3	Financial Disclosures.....	9
4	SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES	9
4.1	Chemistry Manufacturing and Controls	9
4.2	Clinical Microbiology.....	9
4.3	Preclinical Pharmacology/Toxicology	10
4.4	Clinical Pharmacology	10
4.4.1	Mechanism of Action.....	10
4.4.2	Pharmacodynamics.....	10
4.4.3	Pharmacokinetics.....	10
5	SOURCES OF CLINICAL DATA.....	11
5.1	Tables of Studies/Clinical Trials	11
5.2	Review Strategy	11
5.3	Discussion of Individual Studies/Clinical Trials.....	11
5.3.1	Bioavailability and Food Effect Study PR-12111	11
5.3.2	Oral Irritation Study PR-10007 (Report RR-01708).....	13
6	REVIEW OF EFFICACY	18
	Efficacy Summary	18
6.1	Indication	19
6.1.1	Methods	19
7	REVIEW OF SAFETY.....	19
	Safety Summary	19
7.1	Methods.....	19

7.1.1	Studies/Clinical Trials Used to Evaluate Safety	19
7.1.2	Categorization of Adverse Events	20
7.1.3	Pooling of Data Across Studies to Estimate and Compare Incidence	20
7.2	Adequacy of Safety Assessments	21
7.2.1	Overall Exposure at Doses/Durations and Demographics	21
7.2.2	Explorations for Dose Response.....	21
7.2.3	Special Animal and/or In Vitro Testing	21
7.2.4	Routine Clinical Testing	21
7.2.5	Metabolic, Clearance, and Interaction Workup	21
7.2.6	Evaluation for Potential Adverse Events for Similar Drugs in Drug Class ..	21
7.3	Major Safety Results	21
7.3.1	Deaths.....	21
7.3.2	Nonfatal Serious Adverse Events	22
7.3.3	Dropouts and/or Discontinuations	22
7.4	Supportive Safety Results	22
7.4.1	Common Adverse Events	22
7.4.2	Laboratory Findings	23
7.4.3	Vital Signs	23
7.4.4	Electrocardiograms (ECGs)	23
7.4.5	Special Safety Studies/Clinical Trials	23
7.4.6	Immunogenicity	23
7.5	Other Safety Explorations.....	23
7.5.1	Dose Dependency for Adverse Events	23
7.5.2	Time Dependency for Adverse Events.....	23
7.5.3	Drug-Demographic Interactions	23
7.5.4	Drug-Disease Interactions.....	24
7.5.5	Drug-Drug Interactions.....	24
7.6	Additional Safety Evaluations	24
7.6.1	Human Carcinogenicity	24
7.6.2	Human Reproduction and Pregnancy Data.....	24
7.6.3	Pediatrics and Assessment of Effects on Growth	24
7.6.4	Overdose, Drug Abuse Potential, Withdrawal and Rebound.....	24
7.7	Additional Submissions / Safety Issues	24
7.7.1	4-Month Safety Update and Annual Report	24
8	POSTMARKET EXPERIENCE.....	25
9	APPENDICES	25
9.1	Literature Review/References	25
9.2	Labeling Recommendations	25
9.3	Advisory Committee Meeting.....	26

Table of Tables

Table 1: Summary of Relevant Clinical Studies	11
Table 2: Visit Schedule for Study 10007	15
Table 3: Demographics in Study 10007	16
Table 4: Number (%) of Subjects with Gingival Irritation and Inflammation.....	17
Table 5: Common Adverse Events in Study 10007 (N = 56).....	18

List of Abbreviations and Definitions

AE	Adverse event
BMI	Body mass index
CI	Confidence interval
CHC	Combination hormonal contraceptive
COC	Combination oral contraceptive
DBRUP	Division of Bone, Reproductive and Urologic Products
EE	Ethinyl estradiol
FDA	Food and Drug Administration
FF	Ferrous fumarate
GCP	Good clinical practice
NETA	Norethindrone acetate
NDA	New Drug Application
NE	Norethindrone
OC	Oral contraceptive
ODE III	Office of Drug Evaluation III
OSI	Office of Scientific Investigation
PI	Pearl Index
SAE	Serious adverse event
VTE	Venous thromboembolism

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.